Ocio, E. (. M., Perrot, A. (., Bories, P. (., San-Miguel, J. (. F., Blau, I. (. W., Karlin, L. (., . . . Moreau, P. (. (2023). Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation.
Citación estilo ChicagoOcio, E.M. (Enrique M.)|||/items/2e2c579b-5c69-4327-bbef-0107e8ab4f2e, et al. Efficacy and Safety of Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Ineligible/with No Immediate Intent for Autologous Stem Cell Transplantation. 2023.
Cita MLAOcio, E.M. (Enrique M.)|||/items/2e2c579b-5c69-4327-bbef-0107e8ab4f2e, et al. Efficacy and Safety of Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Ineligible/with No Immediate Intent for Autologous Stem Cell Transplantation. 2023.